Ac-YVAD-CHO acetate
Ac-YVAD-CHO (L-709049) acetate is a potent, reversible, specific tetrapeptide interleukin-lβ converting enzyme (ICE) inhibitor with mouse and human Ki values of 3.0 and 0.76 nM. Ac-YVAD-CHO acetate is also a caspase-1 inhibitor. Ac-YVAD-CHO acetate can suppress the production of mature IL-lβ.
For research use only. We do not sell to patients.
- Formula: C25H36N4O10
- Molecular Weight:552.57
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
|
Caspase-1 |
IL-1β |
In Vitro
Ac-YVAD-CHO acetate inhibits mouse and human IL-1β with IC50 values of 2.5 and 0.7 μM respectively[1].
Ac-YVAD-CHO (0.01-100 μM) acetate reduces the elevations of IL-lβ in the plasma and peritoneal fluid treated with LPS[1].
Ac-YVAD-CHO (15.6 μM) acetate reduces NO-induced thymocyte apoptosis[3].
Ac-YVAD-CHO (15.6 μM, 12 h) acetate inhibits NO-induced PARP cleavage in SNAP-treated thymocytes[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SNAP-treated thymocytes
-
Concentration:15.6 μM
-
Incubation Time:12 h
-
Result:Reduced PARP cleavage.
In Vivo
Ac-YVAD-CHO (2-8 μg, intrastriatal infusion) acetate attenuates Quinolinic acid (QA)-induced apoptosis in rat striatum[2].
Ac-YVAD-CHO (10 and 50 mg/kg; i.p.; 1 hour) acetate is cleared from the blood rapidly, and drops precipitously to approximately 1 and 0.2 μM at 30 and 60 minutes after injection[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:P. acnes-sensitized mice[1]
-
Dosage:50 mg/kg
-
Administration:I.p.
-
Result:Suppressed IL-1β levels in blood.
-
Animal Model:Quinolinic acid-treated Rats[2]
-
Dosage:2-8 μg
-
Administration:Intrastriatal infusion.
-
Result:Attenuated Quinolinic acid (QA)-induced increases in p53 and apoptosis in rat striatum.
Inhibited QA-induced increases in caspase-1 activity and p53 protein levels, with no effect on QA-induced IκB-α degradation, NF-κB or AP-1 activation.
Chemical Information
-
Molecular Weight 552.57
-
Formula C25H36N4O10
-
SMILES
OC(C=C1)=CC=C1C[C@H](NC(C)=O)C(N[C@@H](C(C)C)C(N[C@@H](C)C(N[C@H](C=O)CC(O)=O)=O)=O)=O.CC(O)=O
-
Synonyms
L-709049 acetate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
[1]. Fletcher DS, et al. A synthetic inhibitor of interleukin-1 beta converting enzyme prevents endotoxin-induced interleukin-1 beta production in vitro and in vivo. J Interferon Cytokine Res. 1995;15(3):243-248. [Content Brief]
[2]. Cao Y, et al. Caspase-1 inhibitor Ac-YVAD-CHO attenuates quinolinic acid-induced increases in p53 and apoptosis in rat striatum. Acta Pharmacol Sin. 2005 Feb;26(2):150-4. [Content Brief]
[3]. Zhou X, et al. Nitric oxide induces thymocyte apoptosis via a caspase-1-dependent mechanism. J Immunol. 2000 Aug 1;165(3):1252-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)